SOUTH SAN FRANCISCO, Calif., Sept. 9, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced changes to the Board of Directors, including the appointment of Gerald McMahon, Ph.D. and the impending retirement of William Shiebler and Mark Kessel, each of whom having chosen to serve the remainder of their current terms on the Board of Directors but declining to stand for reelection at OXiGENE’s upcoming 2011 Annual Meeting of the Stockholders to be held in the Fall.
